New hope for hard-to-treat cancers? early trial launches for GV20-0251
NCT ID NCT07106827
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new drug called GV20-0251 in people with advanced solid tumors (like liver, lung, or skin cancer) that have stopped responding to standard therapies. The main goal is to check the drug's safety in a small group of 10 patients. It is not a cure, but aims to control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital
RECRUITINGChengdu, Sichuan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pancreatic Cancer's inflammatory footprint be stopped?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can new drug cocktails reawaken the immune system against melanoma?
- Blood and gut clues may flag pancreatic cancer risk early
- What raises endometrial cancer risk in black women? a study digs in
- Can a new drug combo shrink Hard-to-Treat tumors?